Epithelial ovarian cancer has a poor prognosis owing to late diagnosis and frequent relapse after first-line therapy. Analysis of individual genetic variability could aid in the identification of markers, which could help in stratifying patients with the aim of optimizing individual therapy. In this study we assessed polymorphisms in three genes important in drugs' response in 97 early and 235 late-stage ovarian cancer patients. The Asp1104His polymorphism in xpg, a gene important for removal of platinum adducts, was associated with progression-free survival in early-and late-stage ovarian cancer. Our data indicate that a simple diagnostic analysis such as xpg genotyping can help in predicting response, and extension to other possibly relevant genotypes could be useful in selecting patients with epithelial ovarian cancer for optimal therapy and hence increase the chance of response.

Caiola, E., Porcu, L., Fruscio, R., Giuliani, D., Milani, R., Torri, V., et al. (2013). DNA-damage response gene polymorphisms and therapeutic outcomes in ovarian cancer. PHARMACOGENOMICS JOURNAL, 13(2), 159-172 [10.1038/tpj.2011.50].

DNA-damage response gene polymorphisms and therapeutic outcomes in ovarian cancer

FRUSCIO, ROBERT;GIULIANI, DANIELA;MILANI, RODOLFO;
2013

Abstract

Epithelial ovarian cancer has a poor prognosis owing to late diagnosis and frequent relapse after first-line therapy. Analysis of individual genetic variability could aid in the identification of markers, which could help in stratifying patients with the aim of optimizing individual therapy. In this study we assessed polymorphisms in three genes important in drugs' response in 97 early and 235 late-stage ovarian cancer patients. The Asp1104His polymorphism in xpg, a gene important for removal of platinum adducts, was associated with progression-free survival in early-and late-stage ovarian cancer. Our data indicate that a simple diagnostic analysis such as xpg genotyping can help in predicting response, and extension to other possibly relevant genotypes could be useful in selecting patients with epithelial ovarian cancer for optimal therapy and hence increase the chance of response.
Articolo in rivista - Articolo scientifico
polymorphism; mdm2; ercc1; ercc5/xpg; ovarian cancer; SNP
English
159
172
14
Caiola, E., Porcu, L., Fruscio, R., Giuliani, D., Milani, R., Torri, V., et al. (2013). DNA-damage response gene polymorphisms and therapeutic outcomes in ovarian cancer. PHARMACOGENOMICS JOURNAL, 13(2), 159-172 [10.1038/tpj.2011.50].
Caiola, E; Porcu, L; Fruscio, R; Giuliani, D; Milani, R; Torri, V; Broggini, M; Marabese, M
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/28706
Citazioni
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 14
Social impact